September 01, 2017
Bulletin interne de l'Institut Pasteur
Languages
BIP : The Institut Pasteur Newsletter, September 1, 2017
The Institut Pasteur sponsors and takes part in clinical trials designed to speed up the clinical development of diagnostic tests, health products (vaccines, medicines, etc.) and other therapies. In regulatory terms, the stages in a clinical trial are governed by a strict national and international framework.
The Inception program is launching a call for the recruitment of PhD students in transversal and interdisciplinary projects aimed at understanding the emergence of pathologies through individuals and populations.
On 3 Aug, 2017, Institut Pasteur Korea (IPK, CEO: Dr. Wang-Shick Ryu) and the New Drug Development Center and the Laboratory Animal Center of K-Bio Health signed an MOU for a new drug discovery research collaboration on liver cancer. Despite liver cancer being one of the most frequent cancer globally, there are only a few effective ways to prevent or treat it.
Each month, the Institut Pasteur Scientific Council organizes a lecture by a scientist on campus.
At the Pasteur Medicine Quarter-Hour sessions, two doctors give a brief presentation to Institut Pasteur scientists on the diseases they are involved in treating.
The subject of the next session will be "Research inside companies" with three speakers: Jean-Pierre Vors (Bayer), Georges Azar (Sanofi) and Pierre Sonigo (IEA de Nantes).
The Microbes and Brain MOOC, directed by Grégoire Chevalier and Ivo Gomperts-Boneca, is now open for registration on the FUN platform. This Institut Pasteur MOOC looks at all aspects of the interactions between microbes and the nervous system. After examining the topic from an infectious perspective, it goes on to explore the role of the microbiota in brain function and its potential impact on neurological disorders.
This year's annual appraisals and career development reviews have begun on June 21 and will run until Friday September 29, 2017.
The latest issue of the quarterly newsletter for Institut Pasteur donors – the "Lettre de l'Institut Pasteur" (LIP) – contains a special feature on the two most widespread neurodegenerative diseases in France, Alzheimer's and Parkinson's. Expectations for a breakthrough in treating these diseases have never been higher.
The Risk Prevention Department (SPR) launches a satisfaction survey concerning its services offer.
To improve security at access points and in view of the applicable regulatory directives, biometric readers are currently being installed at the BSL-3 laboratories and A3 and Lwoff animal facilities.
Rehearsals for the Institut Pasteur choir will start again on Monday September 11 at 12 noon.